Bausch Health Companies Inc. (NYSE:BHC) Sees Large Decline in Short Interest

Bausch Health Companies Inc. (NYSE:BHCGet Free Report) saw a large drop in short interest in September. As of September 15th, there was short interest totalling 18,600,000 shares, a drop of 6.2% from the August 31st total of 19,830,000 shares. Currently, 5.8% of the company’s stock are short sold. Based on an average trading volume of 3,760,000 shares, the days-to-cover ratio is presently 4.9 days.

Insider Buying and Selling

In other Bausch Health Companies news, EVP Seana Carson sold 13,370 shares of the company’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $6.21, for a total value of $83,027.70. Following the sale, the executive vice president now owns 435,198 shares in the company, valued at $2,702,579.58. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 8.12% of the stock is owned by company insiders.

Institutional Investors Weigh In On Bausch Health Companies

A number of hedge funds have recently modified their holdings of the business. Salem Investment Counselors Inc. bought a new position in Bausch Health Companies in the 1st quarter worth $32,000. Headlands Technologies LLC bought a new stake in Bausch Health Companies during the 2nd quarter worth approximately $35,000. MQS Management LLC purchased a new position in Bausch Health Companies during the second quarter valued at approximately $71,000. Certuity LLC bought a new position in shares of Bausch Health Companies in the second quarter worth approximately $75,000. Finally, Bfsg LLC increased its stake in shares of Bausch Health Companies by 46.7% in the second quarter. Bfsg LLC now owns 11,450 shares of the company’s stock worth $80,000 after purchasing an additional 3,643 shares in the last quarter. Institutional investors own 78.65% of the company’s stock.

Analyst Ratings Changes

BHC has been the topic of a number of recent research reports. Piper Sandler cut Bausch Health Companies from a “neutral” rating to an “underweight” rating and cut their target price for the stock from $9.00 to $3.00 in a research note on Friday, August 2nd. Jefferies Financial Group cut their price objective on shares of Bausch Health Companies from $13.00 to $9.00 and set a “buy” rating on the stock in a research report on Wednesday, August 7th. Royal Bank of Canada decreased their target price on shares of Bausch Health Companies from $10.00 to $8.50 and set a “sector perform” rating for the company in a report on Friday, August 2nd. StockNews.com upgraded shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a report on Wednesday, September 25th. Finally, Truist Financial decreased their price objective on shares of Bausch Health Companies from $8.00 to $7.00 and set a “hold” rating for the company in a report on Thursday, July 25th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $7.33.

View Our Latest Report on Bausch Health Companies

Bausch Health Companies Trading Up 1.3 %

Shares of BHC stock opened at $8.27 on Wednesday. Bausch Health Companies has a 12-month low of $3.96 and a 12-month high of $11.46. The stock has a market capitalization of $2.99 billion, a P/E ratio of -6.67 and a beta of 0.75. The firm’s 50 day moving average is $6.35 and its 200 day moving average is $7.27.

Bausch Health Companies (NYSE:BHCGet Free Report) last issued its quarterly earnings data on Thursday, August 1st. The company reported $0.98 EPS for the quarter, topping the consensus estimate of $0.89 by $0.09. Bausch Health Companies had a negative return on equity of 742.06% and a negative net margin of 5.12%. The company had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.33 billion. During the same quarter in the previous year, the company posted $0.81 earnings per share. As a group, equities analysts predict that Bausch Health Companies will post 3.61 earnings per share for the current year.

Bausch Health Companies Company Profile

(Get Free Report)

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.

Read More

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.